Common Specialities
{{speciality.keyWord}}
Common Issues
{{issue.keyWord}}
Common Treatments
{{treatment.keyWord}}
Dr. Debnarayan Dutta - Oncologist, Ernakulam

Dr. Debnarayan Dutta

90 (10 ratings)
MD, MBBS

Oncologist, Ernakulam

18 Years Experience  ·  1000 at clinic  ·  ₹600 online
Dr. Debnarayan Dutta 90% (10 ratings) MD, MBBS Oncologist, Ernakulam
18 Years Experience  ·  1000 at clinic  ·  ₹600 online
Submit Feedback
Report Issue
Get Help
Feed
Services
Reviews

Personal Statement

To provide my patients with the highest quality healthcare, I'm dedicated to the newest advancements and keep up-to-date with the latest health care technologies....more
To provide my patients with the highest quality healthcare, I'm dedicated to the newest advancements and keep up-to-date with the latest health care technologies.
More about Dr. Debnarayan Dutta

Dr. Debnarayan Dutta is one of the most acclaimed Oncologists in India who holds an experience of curing his patients for 18 years. Besides being a reputed Cancer Specialist, Dr. Dutta is also a Radiation Oncologist and Surgical Oncologist. He completed his MBBS (University of Calcutta) in 1999 and MD (University of Calcutta) in 2006.


Dr. Dutta has been rewarded with ?ASCO Merit Award? for Neuro-oncology. He is a professional member of AROI, IS NO and NSI. He is known for rendering valuable services like Chemotherapy treatment, treatment of Prostate Cancer, treatment of Brain Tumours, treatment of Lung Cancer, Gamma-Knife Radiosurgery and Cyberknife Cancer treatment. He is devoted to giving the best of treatments and is well acquainted with the newest advancements in medical science. He resorts to the latest health technologies to treat his patients with care.


Dr. Debnarayan Dutta is available at Amrita Institute of Medical Sciences, in Ponekkara, Edappally of Ernakulam, Kerala on Mondays, 9 AM till 6 PM.

Info

Education
MD - Universityof Culcatta - 2006
MBBS - Universityof Culcatta - 1999
Languages spoken
English
Awards and Recognitions
ASCO Merit Award' for Neurooncology
Professional Memberships
AROI
ISNO
NSI

Location

Book Clinic Appointment

1000 at clinic
...more
View All

Consult Online

Text Consult
Send multiple messages/attachments. Get first response within 6 hours.
7 days validity ₹600 online
Consult Now

Services

View All Services

Submit Feedback

Submit a review for Dr. Debnarayan Dutta

Your feedback matters!
Write a Review

Patient Review Highlights

"Thorough" 1 review "Very helpful" 1 review

Reviews

Popular
All Reviews
View More
View All Reviews

Feed

Gastrointestinal Malignancies - How Radiosurgery Can Help?

MD, MBBS
Oncologist, Ernakulam
Gastrointestinal Malignancies  - How Radiosurgery Can Help?

Common gastro-intestinal (GI) malignancies are colon cancer, carcinoma rectum and anal canal, pancreatic cancer, cholangiocarcinoma, carcinoma stomach, hepatocellular carcinoma (HCC) and liver metastasis. Other uncommon tumours include gastro-intestinal stromal tumour (GIST), klaskin tumour and neuro-endocrine tumour. Surgery is the treatment option in these tumours. Unfortunately, majority of these tumours are inoperable at presentation and treated with supportive/palliative intent. Majority of these tumours are relatively chemotherapy (CT) resistant. Role of conventional radiation therapy (RT) in gastro-intestinal malignancies are also not well defined in many of these tumours.

Response rate with delivered dose is not acceptable, and dose escalation is not possible with conventional RT without compromising in critical structure (small intestine, duodenum) tolerance. With modern stereotactic whole body RT (SBRT) higher dose of radiation can be delivered in shorter duration and normal tissue tolerance is respected. SBRT has evolved in recent years and also have promise to improve local control in these relative resistant tumours. Pre-operative and adjuvant RT is established in carcinoma of rectum.

In recent years, short course RT (hypofractionated RT, 25 Gy/5 Fr) had shown to be equally effective as conventional RT (1.8-2 Gy/Fr) in inoperable rectal cancer. Role of conventional RT in inoperable pancreatic cancer has been argued in the EORTC study. Whereas, short course RT (fractionated radiosurgery) is slowly being accepted as an option to complete RT early, start adjuvant CT at the earliest and also improve quality of life (QOL). In liver metastasis, radiosurgery is a non-invasive alternative to surgery. Higher equivalent radiation dose delivered with radiosurgery there may have comparable survival function in selected patients.

Radiosurgery is an option in liver tumour close to porta, sub-diaphragmatic location (segment VIII), nodal involvement and in medically inoperable patients. In hepatocellular carcinoma (HCC), fractionated radiosurgery is an option as ‘bridge therapy’ for patients waiting for liver transplant, medically inoperable patients, chemotherapy resistant, post TACE residual and in recurrent HCCs. Radiosurgery is also consider as primary treatment in suitable patients. There is an ongoing multicentric randomized trial comparing chemotherapy and radiosurgery in HCCs.

In uncommon slow growing tumours such as cholangiocarcinoma, neuro-endocrine tumour and klaskin tumour fractionated radiosurgery have excellent response rate and improve symptoms. In conclusion, modern fractionated stereotactic radiosurgery is an option in many of the GI malignancies improves response rate and also may improve QOL. In coming years with publication of more matured data from randomized and prospective phase II studies the role of radiosurgery will be established. ours , 2) require only thermoplastic mask, no need for invasive frame, 3) has inverse planning system, can spare critical structure, 4) there is a ‘intra-fraction’ correction technology with imaging, 5) there is no need to change the source, hence may be more cost effective and 6) can be used to treat extra-cranial tumours also. CyberKnife has a linear accelerator attached with a robot and is capable of treatment from various coplanar and non-coplanar field arrangements. CyberKnife has sub-millimeter accuracy and unmatched dose distribution. 

The advanced technology behind CyberKnife uses image guidance technology and computer-controlled robotics to deliver and extremely precise dose of radiation to targets, avoiding the surrounding healthy tissue, and adjusting for patient and tumor movement during treatment. In conclusion, CyberKnife is an extension of gammaknife radiosurgery delivery system. This machine has immense promise to treat with short course regimens with high dose and improve local control without increasing toxicities.

1 person found this helpful

Renal Cell Carcinoma - How It Can Be Managed?

MD, MBBS
Oncologist, Ernakulam
Renal Cell Carcinoma - How It Can Be Managed?

Patients with metastatic renal cell carcinoma (RCC) to the brain have a very poor prognosis of three months if left untreated. SRS is an effective treatment modality in numerous patients. This case exemplifies the utility of stereotactic radiosurgery (SRS) in prolonging survival and maintaining quality of life in a patient with RCC. 

  • This 64-year-old female patient initially presented to her primary care physician 22 months after a left nephrectomy for RCC with complaints of mild, intermittent headaches and difficulty with balance. An MRI revealed five cerebellar lesions suspicious for intracranial metastasis. The patient's first GKRS treatment targeted four lesions with 22 Gy at the 50% isodose line. She underwent a total of seven GKRS treatments over the next 60 months for recurrent metastases to the brain. 
  • 72 months and 12 months have now passed since her brain metastases were first discovered and since her last GKRS treatment, respectively, and this woman is alive with considerable quality of life and no evidence of metastatic reoccurrence. This case shows that repeated GKRS treatments, with minimal surgical intervention, can effectively treat multiple intracranial lesions in select patients, prolonging survival and avoiding iatrogenic neurocognitive decline while maintaining a high quality of life.

In case you have a concern or query you can always consult an expert & get answers to your questions!

3404 people found this helpful

CyberKnife Therapy of 24 Multiple Brain Metastases From Lung Cancer!

MD, MBBS
Oncologist, Ernakulam
CyberKnife Therapy of 24 Multiple Brain Metastases From Lung Cancer!

Brain metastases from systemic cancer are the most common type of intracranial neoplasm in adults, being almost 10 times more common than primary malignant brain tumors, which cause a significant burden on the management of patients with advanced cancer (1). The lungs represent one of the most frequent sources of metastases to the brain, with a probability of (36–64%) (3). Symptoms suffered by the patients include headaches, epilepsy, focal weakness, numbness or changes in mental status. The prognosis of patients with brain metastases is not optimistic and the median survival time is ∼1–2 months if left untreated. The 1-year survival rate has been recorded as 10.4% (4,5). The treatment of metastatic brain tumors is complex; not only due to being able to provide local control and improve neurological function, but also due to factors such as age, performance and systemic disease status and the size, volume, location and number of metastases at presentation

CyberKnife is a robotic radiosurgery system with a linear particle accelerator (linac), which is coupled with real-time imaging to track and compensate for the patient’s or target’s motion. As a relatively non-invasive treatment modality, CyberKnife demonstrates certain benefits, including a more accurate target localization and improved dose delivery for the management of metastatic brain tumors that allows higher biologically effective dose delivery without increased incidence of toxicity.

In the present case, the results for the treatment of multiple brain metastases after CyberKnife surgery with a 7–8 Gy marginal dose was promising. CyberKnife for metastatic brain tumors is an effective and safe method for reducing the marginal dose prescribed for multiple brain metastases and for minimizing the radiation-related neurotoxicities. In conclusion, CyberKnife, a focused, highly-targeted radiosurgery and fractionated radiotherapy is particularly useful for multiple brain metastases. CyberKnife provides the advantage of the management of local recurrence and a tolerable complication rate. Although the treatment of brain metastases has been performed with CyberKnife, the clinical significance and optimal dose fractionation scheme require further investigation.

In case you have a concern or query you can always consult an expert & get answers to your questions!

3230 people found this helpful

Choroidal Haemangioma (Eye Lesion) - How Cyberknife Therapy Can Help?

MD, MBBS
Oncologist, Ernakulam
Choroidal Haemangioma (Eye Lesion) - How Cyberknife Therapy Can Help?

Radiation therapy is one of the most important tools to combat cancer. However, conventional radiation therapy is long course (usually 6 to 7 weeks) treatment and may have severe acute side effects including skin and mucosal reactions, diarrhea, feeding difficulties and others. Higher dose radiation is also not possible to deliver due to limitations related to toxicities. CyberKnife is a precise radiation therapy technique by which high dose radiation therapy can be delivered only to the tumor and minimal dose to the normal structures.

  • CyberKnife treatment is a short course treatment (usually only one to 5 days) and have no or minimal side effects. Many tumors which are ‘resistant’ to conventional radiation are ‘sensitive’ to high dose radiation delivered by CyberKnife. “CyberKnife has unique system that it can track moving tumors and treat them with immaculate accuracy”. Tumors in moving organs such as lung and liver can be treated most effectively CyberKnife. Dr Debnarayan Dutta, Consultant in Radiation Oncology at Apollo Speciality Hospital, Chennai commented “there are few tumors which were thought to be not treatable are now being treated successfully with CyberKnife”.
  • Master ShreeVaishnav, a 6 year old boy from Kerala suffering with choroidal haemangioma (eye lesion) had vision loss in both the eyes, he was referred from Sankar Netralaya for treatment. He was treated with CyberKnife and at 2 months follow up evaluation his vision had dramatically improved. “We are thankful to Dr Dutta for giving vision back to my son” told Shree Vaishnav’s father who was elated about CyberKnife. “CyberKnife has opened a modern and effective option for these diseases and we are happy with the result” said Dr Prativa Mishra, eye specialist involved in Shree Vaishnav’s treatment.
  • CyberKnife is a revolution in cancer treatment; it provides effective, short course, minimal toxic and high dose treatment in brain, lung, liver, pancreas, prostate, head and neck and many other tumors.

In case you have a concern or query you can always consult an expert & get answers to your questions!

 

180 people found this helpful

Klatskin Tumour - Understanding It In Detail!

MD, MBBS
Oncologist, Ernakulam
Klatskin Tumour - Understanding It In Detail!

A fifty-four years old Marwari patient from Assam presented with progressive jaundice and intermittent episodes of abdominal pain for three months. CT scan of abdomen showed a small (1.5 x 1.5 cm) mass in the bifurcation of common bile duct which is causing biliary tract obstruction and hence jaundice. Portal nodes were not enlarged and there was no lesion in the liver parenchyma. At presentation, serum bilirubin level was high (14.7 mg/dl). Endoscopic biopsy and brushing cytology was adenocarcinoma and clinic-radiological diagnosis was ‘Klatskin tumour’. 

  • Metallic stenting was done to relieve jaundice and after stenting serum bilirubin level came down rapidly. PET scan showed increased uptake in the biliary duct region mass without any sign of metastasis. He was evaluated and planned for treatment with robotic radiosurgery. He was treated using robotic radiosurgery (CyberKnife) with high precision radiotherapy technique after fiducial placement (gold seeds) near the tumour. After one year, the patient had no obvious complain, liver function (no jaundice) was normal and CT scan evaluation showed completed resolution of the mass.  
  • Klatskin tumour is an uncommon tumour that arises from the bifurcation of common bile duct in the abdomen (duct that drains bile from liver). Patients usually present with progressive (increasing) persistent jaundice followed by pain in the upper abdomen. Surgical excision is the mainstay of treatment. However, surgery is not possible in majority of the patients owing to the location of the tumour, high jaundice and medical condition. Chemotherapy may not be an optimal option in majority of the patients as they present with high jaundice. Majority of such patients with poor medical condition are treated with only supportive care and prognosis is dismal (survival for a few months only).
  • Patients with metallic stent have relief from jaundice but unfortunately in a few weeks time, the stent gets blocked with tumour growth. Patients again present with high jaundice and have severely impaired quality of life. They complain of severe itching of entire body, loss of appetite and succumb due to impaired liver function from high jaundice/obstruction. The treatment is to have a longer ‘jaundice-free period’ which in turn improves quality of life and possibly survival function as well.  
  • Stereotactic body radiation therapy’s high dose radiation ‘sterilizes’ the metallic stent and bile duct region. It is assumed that with radiation therapy, blockage of bile duct and stent is delayed and patients have longer jaundice-free period.In Klatskin tumour, CyberKnife allows to deliver high dose of radiation in a short duration to the target without significant morbidity. If you wish to discuss about any specific problem, you can consult an Oncologist.
3107 people found this helpful

Brain Tumors - How Radiosurgery Can Help?

MD, MBBS
Oncologist, Ernakulam
Brain Tumors - How Radiosurgery Can Help?

Short course radiation therapy is the one of the most talked about subject in recent years and also a fascinating research zone. Hypofractionated radiation therapy is an old concept, but only in recent years with tremendous improvement in radiation therapy delivery technologies there is a significant visible surge in it’s applicability in clinical practice. Modern radiation therapy technology is capable of delivering high dose to the target while sparing majority of the adjacent critical structures. Hence, it is possible to deliver short course of treatment regimen with higher dose per fraction without increasing in toxicity. In brain tumours, radiosurgery with gamma-knife is considered standard of care in many of the clinical indications such as small meningiomas, acaustic schwannomas, residual low grade gliomas, AVMs and solitary/ oligo brain metastasis. Gamma-knife radiosurgery is in clinical practice for more than five decades.

There are several prospective and randomized studies (level I evidence) with long-term follow up data supporting the use of radiosurgery in these clinical indications. Other indications of radiosurgery are pituitary tumour, craniopharyngiomas, glomus tumours, chordomas and others. Robotic radiosurgery (CyberKnife®) is precision radiosurgery delivery system and an extension of gamma-knife system. CyberKnife uses the principle of gamma-knife, but with linear accelerator source instead of multiple cobalt sources. CyberKnife is capable to treating all tumours indicated for gamma-knife with similar accuracy.

This modern tool has some additional advantages from gamma-knife, such as

1) CyberKnife can use fractionated treatment, hence relatively larger tumours can be treated.

2) Require only thermoplastic mask, no need for invasive frame.

3) Has inverse planning system, can spare critical structure.

4) There is a ‘intra-fraction’ correction technology with imaging.

5) There is no need to change the source, hence may be more cost effective.

6) Can be used to treat extra-cranial tumours also. CyberKnife has a linear accelerator attached with a robot and is capable of treatment from various coplanar and non-coplanar field arrangements. CyberKnife has sub-millimeter accuracy and unmatched dose distribution.

The advanced technology behind CyberKnife uses image guidance technology and computer-controlled robotics to deliver and extremely precise dose of radiation to targets, avoiding the surrounding healthy tissue, and adjusting for patient and tumor movement during treatment. In conclusion, CyberKnife is an extension of gammaknife radiosurgery delivery system. This machine has immense promise to treat with short course regimens with high dose and improve local control without increasing toxicities. If you wish to discuss about any specific problem, you can consult an Oncologist.

2943 people found this helpful
View All Feed